{"id":56,"date":"2023-07-05T08:06:50","date_gmt":"2023-07-05T07:06:50","guid":{"rendered":"http:\/\/tris.sambrownprojects.com\/?page_id=56"},"modified":"2024-08-21T08:33:19","modified_gmt":"2024-08-21T12:33:19","slug":"home-page","status":"publish","type":"page","link":"https:\/\/www.trispharma.com\/","title":{"rendered":"Home Page"},"content":{"rendered":"
[vc_row full_width=”stretch_row” video_bg=”yes” video_bg_url=”\/wp-content\/uploads\/2023\/08\/TRIS-Glacier-Hero-video.mp4″ conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” css=”.vc_custom_1723534809867{background-image: url(https:\/\/www.trispharma.com\/wp-content\/uploads\/2024\/08\/TRIS-Glacier-Hero-video.jpg?id=3111) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” el_class=”rw-home-banner”][vc_column width=”1\/2″][\/vc_column][vc_column width=”1\/2″ css=”.vc_custom_1690987627500{padding-top: 70px !important;}” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”bn-text-col”][vc_column_text css=”” el_class=”text-white text-hero”]<\/p>\n
At Tris Pharma, we\u2019re on a mission to uniquely solve some of the most intractable therapeutic challenges in ADHD, pain, addiction and other diseases of the central nervous system<\/span>[\/vc_column_text] [\/vc_column_text][vc_row_inner][vc_column_inner width=”1\/6″][\/vc_column_inner][vc_column_inner width=”2\/3″][vc_video link=”https:\/\/vimeo.com\/855795648\/026a2ec582?share=copy” align=”center”][\/vc_column_inner][vc_column_inner width=”1\/6″][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row full_width=”stretch_row_content_no_spaces” equal_height=”yes” content_placement=”middle” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”half-rw-spacing bg-image-office-rw”][vc_column width=”1\/2″ text_align=”center” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”bg-image-clinic”][\/vc_column][vc_column width=”1\/2″ text_align=”center” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” css=”.vc_custom_1691483643908{background-position: center !important;background-repeat: no-repeat !important;background-size: contain !important;}” el_class=”bg-half-clinic”][vc_column_text css=”” el_class=”bg-half-image-txt txt-blue width-innovation”]<\/p>\n We create high-quality, patient-friendly therapeutics that deliver maximum benefit to patients.[\/vc_column_text] Our approved medicines and investigational compounds are designed to provide benefits that are not available from currently approved therapies.[\/vc_column_text] [\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” wrap_container=”yes” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”sec-typo nav-boxes”][vc_column width=”1\/3″ text_align=”center” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”box-container-border”][vc_single_image image=”564″ img_size=”full” alignment=”center” css=”.vc_custom_1690908133675{margin-bottom: 0px !important;}” el_class=”icon”][vc_column_text css=”.vc_custom_1701343311456{margin-bottom: 20px !important;}” el_class=”icon-text-block box-text”]<\/p>\n Tris Pharma\u2019s proprietary, innovative LiquiXR\u00ae<\/sup><\/em> technology has powered the development of more than a dozen medicines and programs<\/p>\n [\/vc_column_text][\/vc_column][vc_column width=”1\/3″ text_align=”center” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”box-container-border”][vc_single_image image=”550″ img_size=”full” alignment=”center” css=”.vc_custom_1690908156816{margin-bottom: 0px !important;}” el_class=”icon”][vc_column_text css=”.vc_custom_1701343339857{margin-bottom: 20px !important;}” el_class=”icon-text-block box-text”]<\/p>\n Tris Pharma has developed a portfolio of four leading ADHD therapies that enhance patient care and experience for both adults and children with the disorder<\/p>\n [\/vc_column_text][\/vc_column][vc_column width=”1\/3″ text_align=”center” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”box-container-border”][vc_single_image image=”615″ img_size=”full” alignment=”center” css=”.vc_custom_1691146637754{margin-bottom: 0px !important;}” el_class=”icon”][vc_column_text css=”.vc_custom_1716374581705{margin-bottom: 20px !important;}” el_class=”icon-text-block box-text”]<\/p>\n We have a robust pipeline of investigational therapies with the potential to address the unmet needs of patients living with ADHD, pain, addiction and other diseases of the central nervous system<\/p>\n [\/vc_column_text][\/vc_column][\/vc_row][vc_row wrap_container=”yes” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”sp-mb-news sp-news”][vc_column text_align=”center” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column_text css=”.vc_custom_1691483837895{margin-bottom: 0px !important;}”]<\/p>\n [\/vc_column_text][vc_column_text css=”.vc_custom_1689957660891{margin-bottom: 0px !important;border-bottom-width: 4px !important;padding-bottom: 20px !important;border-bottom-color: #f29557 !important;border-bottom-style: solid !important;}” el_class=”border-org”][\/vc_column_text][\/vc_column][\/vc_row][vc_row wrap_container=”yes” equal_height=”yes” content_placement=”middle” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” css=”.vc_custom_1692708747782{border-bottom-width: 2px !important;border-bottom-color: #dbdbdb !important;border-bottom-style: solid !important;}” el_class=”spacing-left-right press-release-section-title”][vc_column width=”1\/4″ conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column_text el_class=”featured-pressrelease-title”]FEATURED PRESS RELEASE[\/vc_column_text][\/vc_column][vc_column width=”3\/4″][\/vc_column][\/vc_row][vc_row wrap_container=”yes” equal_height=”yes” content_placement=”middle” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” css=”.vc_custom_1692708491683{border-bottom-width: 2px !important;border-bottom-color: #dbdbdb !important;border-bottom-style: solid !important;}” el_class=”spacing-left-right press-release-news featured-press-releases”][vc_column conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column_text el_class=”text-skyblue icon-set”]At Tris Pharma, we are inspired by and dedicated to making a profound impact on the lives of patients around the world.<\/h2>\n
COMMITMENT TO PATIENTS<\/h6>\n
Therapies With Real Impact<\/h3>\n
INNOVATION<\/h6>\n
Differentiated Therapeutic Approaches<\/h3>\n
We are committed to using our industry-leading capabilities and innovative, proprietary technologies to develop and deliver effective therapies for patients around the world suffering from ADHD, pain, addiction and other diseases of the central nervous system.<\/h2>\n
Platform<\/h4>\n
Learn more<\/a><\/h5>\n
Medicines<\/h4>\n
Learn more<\/a><\/h5>\n
Pipeline<\/h4>\n
Learn more<\/a><\/h5>\n
Latest News<\/h2>\n
<\/div>
August 21, 2024<\/h4>
Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat Pain<\/a><\/h2><\/div><\/div><\/div>[\/vc_column_text][\/vc_column][\/vc_row][vc_row wrap_container=”yes” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”spacing-left sp-release”][vc_column][vc_column_text]